INS and type 2 diabetes mellitus: The results of this indirect treatment comparison demonstrate that, among patients with type 2 diabetes uncontrolled on basal insulin, treatment with IDegLira resulted in a greater reduction of HbA1c and higher odds of reaching HbA1c < 7% compared with iGlarLixi [14].